Association between UCP2 A55V polymorphism and risk of cardiovascular events in patients with multi-vessel coronary arterial disease
Carregando...
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOMED CENTRAL LTD
Citação
BMC MEDICAL GENETICS, v.14, article ID 40, 7p, 2013
Resumo
Background: UCP2 (uncoupling protein 2) plays an important role in cardiovascular diseases and recent studies have suggested that the A55V polymorphism can cause UCP2 dysfunction. The main aim was to investigate the association of A55V polymorphism with cardiovascular events in a group of 611 patients enrolled in the Medical, Angioplasty or Surgery Study II (MASS II), a randomized trial comparing treatments for patients with coronary artery disease and preserved left ventricular function. Methods: The participants of the MASS II were genotyped for the A55V polymorphism using allele-specific PCR assay. Survival curves were calculated with the Kaplan-Meier method and evaluated with the log-rank statistic. The relationship between baseline variables and the composite end-point of cardiac death, acute myocardial infarction (AMI), refractory angina requiring revascularization and cerebrovascular accident were assessed using a Cox proportional hazards survival model. Results: There were no significant differences for baseline variables according genotypes. After 2 years of follow-up, dysglycemic patients harboring the W genotype had higher occurrence of AMI (p=0.026), Death+AMI (p=0.033), new revascularization intervention (p=0.009) and combined events (p=0.037) as compared with patients carrying other genotypes. This association was not evident in normoglycemic patients. Conclusions: These findings support the hypothesis that A55V polymorphism is associated with UCP2 functional alterations that increase the risk of cardiovascular events in patients with previous coronary artery disease and dysglycemia.
Palavras-chave
UCP2, A55V polymorphism, Coronary artery disease, Diabetes
Referências
- Arsenijevic D, 2000, NAT GENET, V26, P435
- Astrup A, 1999, INT J OBESITY, V23, P1030, DOI 10.1038/sj.ijo.0801040
- Beitelshees AL, 2010, PHARMACOGENET GENOM, V20, P231, DOI 10.1097/FPC.0b013e3283377abc
- Blanc J, 2003, CIRCULATION, V107, P388, DOI 10.1161/01.CIR.0000051722.66074.60
- Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
- Cha MH, 2007, METABOLISM, V56, P806, DOI 10.1016/j.metabol.2007.01.023
- Cheurfa N, 2008, DIABETES, V57, P1063, DOI 10.2337/db07-1292
- D'Adamo M, 2004, DIABETES, V53, P1905, DOI 10.2337/diabetes.53.7.1905
- Dalgaard LT, 2011, J OBES, V2011, DOI 10.1155/2011//340241
- Dhamrait SS, 2004, EUR HEART J, V25, P468, DOI 10.1016/j.ehj.2004.01.007
- Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269
- Hueb W, 2004, J AM COLL CARDIOL, V43, P1743, DOI 10.1016/j.jacc.2003.08.065
- Hueb W, 2007, CIRCULATION, V115, P1082, DOI 10.1161/CIRCULATIONAHA.106.625475
- Klannemark M, 1998, EUR J ENDOCRINOL, V139, P217, DOI 10.1530/eje.0.1390217
- Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203
- McLeod CJ, 2005, J BIOL CHEM, V280, P33470, DOI 10.1074/jbc.M505258200
- MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
- Myakishev MV, 2001, GENOME RES, V11, P163, DOI 10.1101/gr.157901
- Norhammar A, 2002, LANCET, V359, P2140, DOI 10.1016/S0140-6736(02)09089-X
- Rance KA, 2007, INT J OBESITY, V31, P1311, DOI 10.1038/sj.ijo.0803535
- Sesti G, 2003, DIABETES, V52, P1280, DOI 10.2337/diabetes.52.5.1280
- Teshima Y, 2003, CIRC RES, V93, P192, DOI 10.1161/01.RES.0000085581.60197.4D
- Xu K, 2011, DIABETOLOGIA, V54, P2315, DOI 10.1007/s00125-011-2245-y
- Yu XH, 2005, CLIN CHEM, V51, P1451, DOI 10.1373/clinchem.2004.044859